Bibliographic Details
| Title: |
Access to Immunoglobulin Treatment for CIDP Patients During the COVID-19 Pandemic. |
| Authors: |
Brissette, Vincent, Poirier, Laurence, Massie, Rami, Chalk, Colin, Moore, Fraser |
| Source: |
McGill Journal of Medicine; 2023, Vol. 21 Issue 1, p1-10, 10p |
| Subject Terms: |
HEALTH services accessibility, CROSS-sectional method, NEUROMUSCULAR diseases, IMMUNOGLOBULINS, SCIENTIFIC observation, PROBABILITY theory, GUILLAIN-Barre syndrome, RETROSPECTIVE studies, DESCRIPTIVE statistics, CHI-squared test, TREATMENT duration, MEDICAL records, ACQUISITION of data, RESEARCH, QUALITY of life, DEMYELINATION, DATA analysis software, COVID-19 pandemic, COVID-19 |
| Geographic Terms: |
CANADA |
| Abstract: |
Background: Immunoglobulin supplies are limited; their access for patients diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may have been difficult during the COVID-19 pandemic. Methods: A retrospective cross-sectional study was conducted with CIDP patients (n=16, 68.8% female, mean age 60.4±11.3) recruited from three Montreal tertiary care institutions. Inclusion criteria were patients over 18 years old whowere receiving immunoglobulin treatment as of March 1st, 2020. Patients were asked to complete a questionnaire inquiring about changes in their immunoglobulin treatment during the pandemic and about their quality of life. Their charts were reviewed by an independent investigator. We used weighted chi-squared statistical tests and Cramer's V correlation ratios to measure associations with treatment change. Results: Eighteen months after the pandemic started, 50% of patients were receiving the same treatment, 25% were receiving immunoglobulin treatment at a different frequency, 6.3% were receiving a different dose, 12.5% were receiving a different dose and frequency, and 6.3% were receiving a different treatment. Reasons associated with treatment change were worsening of neurological condition (18.8%; Cramer's V=0.480; p-value=0.055), improvement of neurological condition (25%; Cramer's V=0.577; p-value=0.021) and reduced availability of treatment (6.3%; Cramer's V=0.258; p-value=0.302). There were no significant correlations between lower quality of life (p-value=0.323) or lower Rasch-built Overall Disability Scale score (p-value=0.574) and treatment change. Conclusion: Difficulty accessing immunoglobulin treatment was infrequent and not significantly associated with treatment change for CIDP patients during the COVID-19 pandemic. A larger multicentre study across multiple sites might identify other treatment access problems resulting from the pandemic. [ABSTRACT FROM AUTHOR] |
|
Copyright of McGill Journal of Medicine is the property of McGill University, Faculty of Medicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
